136 related articles for article (PubMed ID: 32535684)
1. The tissue expression pattern of CA 19.9 is associated with oncological features in medullary thyroid carcinoma.
Vargas CVF; Ceolin L; Scheffel RS; Benini AF; Graudenz MS; Maia AL
Endocrine; 2020 Dec; 70(3):544-551. PubMed ID: 32535684
[TBL] [Abstract][Full Text] [Related]
2. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
[TBL] [Abstract][Full Text] [Related]
3. MEDULLARY THYROID CANCER THAT STAINS NEGATIVE FOR CA 19-9 HAS DECREASED METASTATIC POTENTIAL.
Milman S; Arnold JL; Price M; Negassa A; Surks MI; Fleischer N; Whitney KD
Endocr Pract; 2015 Jun; 21(6):590-4. PubMed ID: 25716629
[TBL] [Abstract][Full Text] [Related]
4. Global DNA methylation profile in medullary thyroid cancer patients.
Ceolin L; Goularte APP; Ferreira CV; Romitti M; Maia AL
Exp Mol Pathol; 2018 Aug; 105(1):110-114. PubMed ID: 29935954
[TBL] [Abstract][Full Text] [Related]
5. Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on Clinical Behavior of Medullary Thyroid Carcinoma.
Mishra V; Kowtal P; Rane P; Sarin R
Asian Pac J Cancer Prev; 2020 May; 21(5):1289-1293. PubMed ID: 32458635
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.
Zhan S; Li J; Wang T; Ge W
Oncologist; 2018 Dec; 23(12):1415-1425. PubMed ID: 29739896
[TBL] [Abstract][Full Text] [Related]
7. CA19-9 as a Predictor of Worse Clinical Outcome in Medullary Thyroid Carcinoma.
Alencar R; Kendler DB; Andrade F; Nava C; Bulzico D; Cordeiro de Noronha Pessoa C; Corbo R; Vaisman F
Eur Thyroid J; 2019 Jul; 8(4):186-191. PubMed ID: 31602360
[TBL] [Abstract][Full Text] [Related]
8. Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease.
Jayakody S; Reagh J; Bullock M; Aniss A; Clifton-Bligh R; Learoyd D; Robinson B; Delbridge L; Sidhu S; Gill AJ; Sywak M
World J Surg; 2018 May; 42(5):1432-1439. PubMed ID: 29484475
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
Bi Y; Ren X; Bai X; Meng Y; Luo Y; Cao J; Zhang Y; Liang Z
Eur J Surg Oncol; 2019 Mar; 45(3):353-358. PubMed ID: 30528043
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
13. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma.
Ferreira LB; Eloy C; Pestana A; Lyra J; Moura M; Prazeres H; Tavares C; Sobrinho-Simões M; Gimba E; Soares P
Eur J Endocrinol; 2016 Apr; 174(4):551-61. PubMed ID: 26811408
[TBL] [Abstract][Full Text] [Related]
15. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medullar thyroid carcinoma patients.
Shabani N; Sheikholeslami S; Paryan M; Zarif Yeganeh M; Tavangar SM; Azizi F; Mohammadi-Yeganeh S; Hedayati M
J Cell Physiol; 2020 Feb; 235(2):1366-1373. PubMed ID: 31297834
[TBL] [Abstract][Full Text] [Related]
16. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.
Scollo C; Baudin E; Travagli JP; Caillou B; Bellon N; Leboulleux S; Schlumberger M
J Clin Endocrinol Metab; 2003 May; 88(5):2070-5. PubMed ID: 12727956
[TBL] [Abstract][Full Text] [Related]
17. The RET polymorphic allele S836S is associated with early metastatic disease in patients with hereditary or sporadic medullary thyroid carcinoma.
Siqueira DR; Romitti M; da Rocha AP; Ceolin L; Meotti C; Estivalet A; Puñales MK; Maia AL
Endocr Relat Cancer; 2010 Dec; 17(4):953-63. PubMed ID: 20801952
[TBL] [Abstract][Full Text] [Related]
18. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
[TBL] [Abstract][Full Text] [Related]
19. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
20. Static Prognostic Factors and Appropriate Surgical Designs for Patients with Medullary Thyroid Carcinoma: The Second Report from a Single-Institution Study in Japan.
Ito Y; Miyauchi A; Kihara M; Higashiiyama T; Fukushima M; Miya A
World J Surg; 2018 Dec; 42(12):3954-3966. PubMed ID: 30051240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]